EDUCATION:
| Ph.D. |
Rice
Graduate Fellow Award, Molecular and cell biology,
Department of Biochemistry and Cell Biology, Rice University
(1984-1988) |
| B.S. |
Biology/Chemistry,
Department of Natural and Applied Sciences, University
of Houston at Clear Lake (1979-1984) |
| A.S. |
Biology/Chemistry,
Department of Biology, San Jacinto College, Houston (1976-1978) |
EXPERIENCE:
CURRENT
POSITION July 2004 to present |
|
Senior
Consultant - Biologics
Consulting Group, Inc., Germantown, MD.
- Provide consulting expertise in CMC product development strategies from pre-Phase I to commercialization, with emphasis on drug substance and drug product characterization, comparability assessment, release and stability testing.
- Review product regulatory submissions for suitability relative to current FDA and EMA expectations for CMC data from biotechnological/biological products.
- Perform gap analysis of sponsor’s internal policies and SOPs to assess suitability of their technical and quality practices for product development activities.
- Provide technical and quality expertise in identity, purity, potency, and stability test method development, validation.
- Provide technical and quality expertise in development and validation of immunogenicity tests (screening, confirmatory and neutralizing assays).
- Perform analytical method troubleshooting and review OOS investigations for biopharmaceuticals.
- Conduct independent quality audits of laboratory compliance activities under GLP and cGMP, and evaluate R&D laboratory quality practices.
- Conduct independent due-diligence audits for pending acquisitions or partnerships to determine gaps in CMC analytical and stability activities.
- Develop and deliver internal and external training sessions on technical, regulatory and quality elements of biological product CMC analytical and stability studies.
- Serve as a subject matter expert on committees for professional societies, technical publications, university undergraduate and graduate programs, and regulatory bodies
|
| |
|
|
| 2002
to 2004 |
|
Contractor,
American Red Cross Plasma Derivatives, Rockville, MD.
- Served as principle CMC RA/QA associate for Plasma
Derivative product development projects.
- Established
and implement R&D quality practice policies ("Good
Development Practices" or "GDP") to
support the development of plasma-derived products
for FDA and international submissions.
- Established
and implement $250K NuGenesis SDMS electronic documentation
system for six product discovery and development laboratories.
- Prepared
internal guidance documents and conduct training sessions
on technical, regulatory and quality elements of biological
product development.
- Prepared
and review FDA IND and BLA submissions for nationally
and internationally manufactured plasma products.
- Participated
in international project teams to plan and execute
regulatory and quality strategies for product development
from Phase I to BLA.
|
| |
|
|
| 2002
to 2004 |
|
Biotechnology
Product Consultant, NMR Biotech, Germantown, MD.
- Provided
expertise on biotechnology product development, laboratory
quality practices, test method validation, product
stability programs, and management of outsourced biopharmaceutical
testing and manufacturing.
- Prepared
and review CMC sections for IND and BLA submissions
for a wide variety of biological and biotechnological
products, participate in IND/BLA meetings with regulators,
and respond to regulatory reviewer questions.
- Conducted
quality audits of US and international facilities
for cGMP and GLP compliance assessment. Design and
review quality system documentation required for laboratory
facilities for R&D, GLP and cGMP.
- Designed
and review protocols for product characterization,
process and test method validation and product stability
programs.
- Presented
seminars and training classes on the technical, regulatory
and quality elements required in biotechnology product
development and commercialization. Serve as subject
matter expert in preparation and review of journal
articles and book chapters.
- Facilitated
professional meetings on biopharmaceutical industry
issues, including interactions among industry and
regulatory bodies.
|
| |
|
|
| 2001
to 2002 |
|
Director
of Technical and Regulatory Affairs, BioReliance
Corporation, Analytical Services Division, Rockville,
MD.
- Served
as the principal point of scientific and regulatory
CMC interaction with over 150 worldwide pharmaceutical
clients for their national and international product
submissions for biotechnology products.
- Provided
expertise on product development requirements for
recombinant proteins, monoclonal antibodies, plasma
products, transgenic proteins, viral vectors, vaccines,
and synthetic biomolecules (e.g. peptides and oligonucleotides).
- Supported
Analytical Division project managers and study directors
to ensure successful design and execution of complex
or custom projects.
- Served
as consultant to clients for technical and regulatory
issues related to the CMC sections of INDs, BLAs,
NDAs, annual reviews and supplements.
- Consulted
internally and externally on quality practices and
compliance issues.
- Developed
and updated corporate Analytical marketing and training
materials.
- Supported
the sales force and other members of the Sales and
Marketing team as Analytical expert for client inquiries.
- Delivered
client presentations, professional seminars and training
classes on biomolecular methods, regulatory product
development guidelines, laboratory management, and
quality/compliance practices.
- Interacted
with regulatory bodies as industry expert and served
as client advocate to regulatory reviewers for product
submissions.
|
| |
|
|
| 1998
to 2000 |
|
Director
of Analytical Services Operations, BioReliance Corporation,
Analytical Services.
- Managed
a $4 million department of 20-24 project managers,
technical writers, study directors and analytical
scientists to provide contract biomolecular analysis
for the characterization, stability and release testing
of over 200 bulk and formulated biotechnology products.
- Designed
and managed CMC analytical studies from pre-Phase
I through Phase III and commercialization.
- Supervised
divisional quality system programs to ensure top-down
GLP and cGMP compliance.
- Served
as the responsible divisional authority for quality
audits conducted by project sponsors, national and
international regulatory officials.
- Implemented
management systems to increase efficiency in resource
scheduling and facilities utilization.
- Developed
budgets, monitored profits and costs, and operated
laboratories and support functions at the highest
levels of responsiveness to meet timelines and deliverables
to clients.
- Successfully
recruited and retained highly skilled scientific staff
in a competitive technical location.
- Improved
and expanded testing services and optimized laboratory
growth to support new client projects.
|
| |
|
|
| 1996
to 1998 |
|
Senior
Scientist, Bulk Biomolecular Products, Abbott Diagnostics
Division, Analytical Development and Validation, Infectious
Diseases Sector R&D, Chicago, IL.
- Served
as a senior technical supervisor of $2.2 million analytical
R&D laboratory with 12 analysts developing and
validating analytical methods for well-characterized
biologicals used in CBER-regulated immunodiagnostic
products.
- Prepared
molecular biology, manufacturing, purification, analytical
characterization and lot release and stability sections
for 12 IND, 6 PLA/BLA submissions, 25 PMA submissions,
and 10 IPMF submissions to international regulatory
agencies.
- Acted
as divisional R&D representative in major technology
transfer projects of antibody and viral bulk products
from contract manufacturing operations.
- Directed
outsourced analytical studies though contract testing
organizations.
- Provided
expertise on Abbott test method and process validation
strategies at the division and corporate levels.
- Established
the Abbott "Quality Technical Reviewer"
model for approval of divisional analytical method
validations and method SOPS to provide greater technical
and quality expertise and increase efficiency.
- Served
as scientific specialist for two 40-member cGMP QC
operations teams that manufactured and tested over
100 biotechnology bulk products from US and international
plants.
|
| |
|
|
| 1992
to 1996 |
|
Senior
Research Biochemist, Biomolecular Products, Abbott
Diagnostics Division, Infectious Diseases Sector R&D,
Chicago, IL.
- Performed
analytical biochemistry of over 75 natural and rDNA
proteins, monoclonal and polyclonal antibodies, and
synthetic peptides using characterization techniques
such as HPLC, amino acid analysis, protein sequencing,
peptide mapping, SDS-PAGE, scanning densitometry,
IEF, immunoblots and assays, capillary electrophoresis,
light scattering, surface plasmon resonance and protein
identification via proteomic databases.
- Prepared
method SOPS, with transfer, training and troubleshooting
of methods to a 30-member QA laboratory.
- Established
ISO-9000 compliance activities in the department,
and served on corporate ISO certification task force.
- Certified
in the use of biohazardous and potentially biohazardous
viral materials, including BL3 biohazard suite access.
- Contributions
to over 125 analytical test method characterizations
and validations.
- Performed
direct supervision and review of 5 R&D laboratory
scientists.
|
| |
|
|
| 1988
to 1992 |
|
Postdoctoral
Research Fellow, University of Texas Dental Branch,
Department of Biological Chemistry, Houston, TX.
- Performed
biochemical characterization of the protein-protein
interactions between the bone protein osteopontin
and other bone extracellular matrix proteins.
- Techniques
included tissue culture, protein purification and
characterization, various ligand binding assays, in
vitro and in vivo radiolabelling of proteins, SDS-PAGE,
immunoblots, and glycoprotein analysis.
|
| |
|
|
| 1984
to 1988 |
|
Graduate
Fellow, Rice University, Department of Biochemistry
and Cell Biology.
- Conducted
molecular and cell biology studies of the subcellular
translocation of glutamine synthetase and other urea
cycle enzymes in shark and stingray tissues.
- Techniques
included DNA and RNA isolation, RIPA, nucleic acid
blots, subcellular fraction purification, kinetic
enzyme assays, immunohistochemistry, radiolabelled
pulse/chase assays, IEF and SDS-PAGE.
- Certified
in the use of beta and gamma radiation emitters.
|
| |
|
|
| 1980
to 1984 |
|
Senior
Research Assistant, University of Texas, Dental
Science Institute, Houston, TX.
- Purification
and comparative biochemical analysis of proteins from
microbial and animal models of biomineralization.
Techniques included microbial culture, lipoprotein
purification and characterization, in vitro mineralization
assays, and Xray diffractometry.
- Contributed
to cartilage extracellular matrix studies aboard Space
Shuttle missions for NASA.
|
| |
|
|
| 1978
to 1980 |
|
Research
Assistant, University of Texas, Dental Science Institute,
Houston, TX.
- Analytical
biochemistry of calcified cells and tissues for the
functional characterization of mineralizing proteolipids.
- Techniques
included microbial and tissue culture, protein concentration
and enzyme assays, and electron microscopy.
|
|
HONORS
AND AWARDS
Who’s Who of American Professional Women – 2005, 2006, 2007, 2008
Pharmaceutical Training Institute Trainer of the Year - 2002
Pharmaceutical Training Institute Trainer of the Month - 2001
BioPharm Featured Ten Outstanding Women of Biotech - 2000
Abbott Diagnostics Division R&D Technology Team Award for Scientific Excellence – 1998
Abbott Diagnostics Annual Outstanding Women Scientists - 1997
Abbott Corporate Chairman's Award for Individual Performance Excellence - 1997
Abbott Diagnostics Division Business Team Quality Award - 1997
Abbott Diagnostics Division Infectious Diseases R&D Director's Award - 1994
American Men and Women of Science - 1992
Outstanding Young Investigator Award, Texas Society for Mineralized Tissue - 1990
Outstanding Graduate Student Award, Association for Women in Science - 1989
Rice University Graduate Fellowship -1984
Outstanding Young Women of America –1979
|
COMMITTEE AND BOARD APPOINTMENTS
University of Maryland Baltimore County (UMBC)
- Biotechnology Career Forum Panelist (2008)
- “From Bench to Business: Biotechnology Career Opportunities”
- Scientific Advisory Board Member (2007)
- Establishment of master’s program curriculum for Applied Biotechnology
Parenteral Drug Association (PDA)
- Co-chair, Analytical Method Development Task Force
California Separations Sciences Society (CaSSS):
- Industry-FDA CMC Strategy Forum Industry Co-Leader, Jan 2007,
- “Current Expectations for Comparability and Stability of Gene Therapy Products”
- Industry-FDA CMC Strategy Forum Industry Co-Leader, Jan 2006,
- “Biotechnology Product Reference Standards”
- Industry-FDA CMC Strategy Forum Industry Co-Leader, July 2005,
- “Biotechnology Product Stability”
- Well-Characterized Biotechnology Product (WCBP) 10th Annual Industry-FDA Meeting; Industry Chair (2006; first female industry chairperson)
- WCBP Workshop Committee Co-Chair (2004); Chair (2005)
- Industry-FDA CMC Strategy Forum Industry Co-Leader, July 2004,
- “Test Method Qualification and Validation”
- Industry-FDA CMC Strategy Forum Permanent Advisory Board Member (2002 – present)
- Industry-FDA CMC Strategy Forum Co-Founder (2002)
- WCBP Program and Workshop Committee Member (2001 – Present)
BioProcess International:
Charter Editorial Board Member (2002 – present)
Pharmaceutical Training Institute:
Scientific Advisory Board (2001 – 2003)
BioProcessing Journal (Williamsburg Bioprocessing Foundation):
Editorial Board Member (2000-2002)
Association for Biomolecular Resource Facilities (ABRF):
- Co-Founder and Chairman, Quality and Compliance Committee (1996-1998)
- ABRF-NIST Peptide Standards Committee (2001 – Present)
- ABRF Annual Professional Society Meeting, Co-Chair (1999)
Association for Women in Science:
President and Board Member, Houston (1984-1992) and Chicago (1994-1998)
|
| BIBLIOGRAPHY |
Chapters
|
| |
Ritter, N.M., et al. Analytical Test Method Development and Method Qualification, PDA Technical Report (in progress) |
| |
|
| |
Ritter, N.M. (editor) Biotechnological/Biological Product Stability – Principles and Practices (in progress). |
| |
|
| |
Ritter, N.M. (chapter) “Selection, Qualification, and Validation of Analytical Test Methods for Product Characterization, Comparability, Release and Stability Testing” in Bioseparation and Bioprocessing, 2nd edition, (G. Subramanian, editor), (in progress). |
| |
|
| |
Ritter, N.M. (chapter) “Analytical Test Methods for Product and Process Impurities” in Advances in Large Scale Biopharmaceutical Manufacturing and Scale Up Production, 2nd Edition, ASM Press and BioPlan Associates, Inc., in progress. |
| |
|
| |
N. Ritter and J. McEntire, “Analytical Test Methods for Biological and Biotechnological Products”, in Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies (A.S. Rathore and G. Sofer, eds), CRC Press, Taylor and Francis Group, Boca Raton, FL, 2005, pp. 227-326. |
| |
|
| |
Remmer, H.A., Ambulos, N.P., Bonewald, L.F., Dougherty, J.D., Eisenstein, E., Fowler, E., Johnson, J., Khatri, A., Lively, M.O., Ritter, N.M., and Weintraub, S. ‘Synthetic Peptides as Certified Analytical Standards’, in Peptide Revolution: Genomics, Proteomics and Therapeutics (Michael Chorev and Tomi K. Sawyer, eds), American Peptide Society (2003). |
| |
|
| |
Calamai, E.G., Krishnamurthy, R., McEntire, J., Pritchett, T., Ritter, N.M., Seely, R. J., Seaver, S., Venkat, K (coordinators/reviewers), Guide to BioAnalytical Methods, BioPharm 14:12 (December, 2001). |
| |
|
| |
Ritter, N., Smith, A., Fowler, B., Canova-Davis, E. Dougherty, J., and Ghrist, B. ‘Laboratory Quality and Compliance’, in The Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis, and Bioseparation, Vol. 4 (Editors-In-Chief, Michael C. Flickinger and Stephen W. Drew), John Wiley & Sons, Inc., pp. 2113-2115 (1999). |
|
Peer-Reviewed Articles
|
| |
Ritter, N.M. and Hayes, T. “Good Development Practice (GDP): Quality Policies to Support Product Development Activities”, BioProcessing International, (manuscript in progress). |
| |
|
| |
Ritter, N.M., Advant, S., Simmerman, H., Advant, S., Hennessey, J., McEntire, J., Joneckis, C, and Mire-Sluis, A. “WCBP CMC Strategy Forum: Industry and Regulatory Perspectives on Analytical Test Method Qualification versus Validation During Biotechnology Product Development”, BioProcess Int 2:8, pp. 32-47 (September, 2004).
|
| |
|
| |
Ritter, N. M. and McEntire, J. “Determining Protein Concentration: Methodology”, BioPharm 15:4, 12-22 (April 2002). |
| |
|
| |
Ritter, N.M. and Wiebe, M. “Validating Critical Reagents Used in cGMP Analytical Testing: Ensuring Method Integrity and Reliable Assay Performance”, BioPharm 14:5, 12-21 (May 2001). |
| |
|
| |
Ritter, N. M. and Fowler, B. “Analytical Laboratory Quality, Part I – General Quality Practices”, J. Biomolecular Techniques, 12:4-10 (2001). |
| |
|
| |
Ritter, N.M., Hayes, T., and Dougherty, J. “Analytical Laboratory Quality, Part II – Analytical Method Validation”, J. Biomolecular Techniques 12:11-15 (2001). |
| |
|
| . |
Smith, A. and Ritter, N. “Considerations in the Validation of Bioanalytical Methods for Protein Characterization”, Applied Biosystems Reporter 22:1994, Applied Biosystems, Inc. (1994). |
| |
|
| |
Ritter, N.M., Farach-Carson, M.C. and Butler, WT. “Evidence for complex formation between osteopontin and osteocalcin”, J. Bone and Mineral Res. 7:877-885 (1992). |
| |
|
| |
D'Souza,RN.,Happonen,R.P.,Ritter,N.M., and Butler,W.T. “Temporal and spatial patterns of TGF-beta expression in developing rat molars”, Arch. Oral Biol. 3 5:957-965 (1990). |
| |
|
| |
Ritter, N.M., Smith, D.D., Jr., and Campbell, J.W. “Glutamine synthetase in liver and brain of the Holocephalan Hydrolagus collie”, J. Exp. Zool. 243:181-188 (1987). |
| |
|
| |
Smith, D.D., Jr., Ritter, N.M. and Campbell, J.W. “Glutamine synthetase isozymes in elasmobranch brain and liver tissues”, J. Biol. Chem. 262:198-202 (1987). |
| |
|
| |
Goldschmidt, M.C., Ritter, N.M. and Ennever, J.J. “Age-dependency of apatite formation in Bacterionema matruchotti”, Microbios Lett. 29:15-17 (1987). |
| |
|
| |
Boyan,B.D.and Ritter,N.M. “Proteolipid-lipid relationships in normal and vitamin-D deficient chick cartilage”, Calcified Tiss. International 36:332-337 (1984). |
|
Page
Updated:
November 5, 2008
|